Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Petzer

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2020
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional studyGerald W Prager, Leopold Oehler, Armin Gerger, et al.
Ejhaem|June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 studyHeinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2020
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional studyGerald W Prager, Leopold Oehler, Armin Gerger, et al.
Ejhaem|June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 studyHeinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Pageof 7